Abstract: A method is provided for authenticating, and establishing and tracking eligibility of a patient to purchase an over-the-counter (OTC) drug from a retailer, the patient using a client device or terminal and the retailer having a server. The server is configured to redirect the client device or terminal to a backend platform to authenticate the patient, access a storage to search for any information that indicates the patient is ineligible to purchase the OTC drug; and without any information that indicates the patient is ineligible, administer a questionnaire to the patient to assess the eligibility for the OTC drug. And the backend platform redirects the client device or terminal back to the server to complete the online sale of the OTC drug to the patient when the patient is eligible, or cancel the online sale of the OTC drug to the patient when the patient is ineligible.

Abstract: Compounds of formula (I), formula (I), processes for their production and their use as pharmaceuticals.

Abstract: A multi-fluid injector system and methods of operation thereof are presented. One embodiment of such a fluid injector system includes an automatic refill procedure for a fluid injector system comprising a fluid injector and an operably engaged syringe. The procedure includes the step of determining, using an electronic control device operably controlling the fluid injector system, whether a fluid injection procedure involving the syringe is impending. If the electronic control device determines that the fluid injection procedure is not impending, such that the automatic refill will not interfere with the fluid injection procedure, an automatic refill of the syringe is initiated.

Abstract: A system and method for promoting and safeguarding the wellbeing of patients in relation to a fluid injection may obtain patient data; determine, based on the patient data, an initial risk prediction for a patient for a fluid injection to be administered to the patient, the initial risk prediction including a probability that the patient experiences at least one adverse event in response to the fluid injection; provide, to a user device, before the fluid injection is administered to the patient, the initial risk prediction; determine, after the fluid injection is started, sensor data associated with the patient; determine, based on the sensor data determined after the fluid injection is started, a current risk prediction including a probability that the patient experiences the at least one adverse event in response to the fluid injection; and provide, to the user device, the current risk prediction.

Abstract: Benzoylamides of the general formula (I) are described as herbicides. In this formula (I), B, X1 and X2 represent N, O or S(O)n, R, Ra, Rb, Rc, Rd and IV represent radicals such as hydrogen, halogen, (C1-C6)-alkyl, (C1-C6)-alkyloxy and cyano.

Abstract: Systems, methods, and computer programs for monitoring the disease progression of a Parkinson's patient are provided. Specifications for a Parkinson's patient may defined in a computer system by a physician. The specifications may contain threshold values. At repeating points in time, a message may including a request to perform a mobility test may be output by the computer system to the patient. Mobility parameters may be determined as a result of the performance of the mobility test. The mobility parameters may be compared with the threshold values to determine one or more deviations between the one or more mobility parameters and the one or more threshold values. The mobility parameters, the deviations, or a combination thereof may be made available to the physician by outputting or storing the mobility parameters or the deviations or by transmitting the mobility parameters or the deviations to a separate computer system.

Abstract: The present disclosure relates generally to topical analgesic compositions comprising nonsteroidal anti-inflammatory drugs, and more specifically to topical gel compositions of naproxen in combination with select neutralizing agents, thereby having enhanced skin permeation and skin retention properties as well as improved aesthetics upon application and drying.

Abstract: The invention relates to solid formulations (especially water-soluble granules (SG)) of insecticide active tetramic acid derivatives, to a process for production thereof and to the use thereof for application of the active ingredients present, especially for drip & drench applications.

Abstract: System for automatically manipulating primary packaging in secondary packaging, comprising a robot having at least one robot arm with a clamping gripper installed at a tool centre point, wherein each tool centre point has a force-torque sensor, an image recording module for recording images of at least the upper segment of the primary packaging, comprising at least two stereo cameras for recording 3-D images, and one or more processors for providing a three-dimensional point cloud, controlling the image recording module and controlling the robot on the basis of the analysis of the three-dimensional point cloud and the measurements from the force-torque sensors.

Abstract: A syringe for delivery of a medical liquid to a container has a body with proximal end, a frustoconical distal end, and a cylindrical sidewall extending between the proximal end and the distal end along a longitudinal axis. The syringe includes a nozzle at a distal portion of the frustoconical distal end of the syringe, the nozzle having a throughbore providing fluid communication between an interior volume of the syringe and a medical connector configured to be connected to the nozzle. The nozzle includes a plurality of longitudinal ribs formed on an inner surface of the nozzle. The syringe is designed so that the plurality of longitudinal ribs directs a flow of a medical fluid along an inner surface of the frustoconical distal end and along an interior surface of the cylindrical sidewall of the syringe under a Coand? effect. Syringe and connector assemblies and methods for reducing a number of bubbles formed in a medical fluid during a syringe filling procedure are also described.

Abstract: The present disclosure relates generally to novel lipid nanoparticle (LNP)-based compositions useful for, e.g., the delivery of a site-specific endonuclease or a nucleic acid molecule encoding same, into a target cell. Some embodiments of the disclosure relate to compositions and methods for editing the genome of a cell, which involve contacting the cell with an LNP composition as described herein.

Abstract: A fluid delivery system and method for determining whether the correct fluid is being drawn into and/or dispensed from a syringe. The system includes a syringe, a fluid injector for drawing fluid into and dispensing fluid from the syringe, one or more sensors adapted to measure a force required to draw the fluid into and/or dispense the fluid from the syringe, a processor in communication with the one or more sensors, and a non-transitory, computer-readable storage medium in operable communication with the processor. The computer-readable storage medium contains one or more programming instructions that, when executed, cause the processor to receive from the one or more sensors one or more measurements of the force required to draw the fluid into and/or dispense the fluid from the syringe and determine from the one or more measurements whether a correct fluid is being drawn into and/or dispensed from the syringe.

Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.

Abstract: The present invention covers a method for preparing 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine (“the compound of formula (I)” in the following) as well as intermediate compounds useful in the preparation of the compound of formula (I). The present invention also covers polymorphic form B of the compound of formula (I) with very high purity.

Abstract: The present invention relates to an unmanned aerial vehicle (UAV) for agricultural weed management. The UAV comprises a control and processing unit (20), and a camera (30). The control and processing unit is configured to control the UAV to fly to a location inside the canopy of a crop and below the vertical height of the crop and/or between a row of a plurality of crops and below the vertical height of the plurality of crops. The control and processing unit is configured to control the camera to acquire at least one image relating to the ground at the location inside the canopy of a crop and below the vertical height of the crop and/or between a row of a plurality of crops and below the vertical height of the plurality of crops. The control and processing unit is configured to analyse the at least one image to determine the presence of at least one weed and its location on the ground.

Abstract: An injector system for delivering a medical fluid may include at least one syringe defining a reservoir operatively connected to a piston; and at least one processor programmed or configured to, based on an air check protocol for detecting air in the reservoir, determine a baseline value comprising baseline compressibility data for the at least one syringe of the injector system, deliver the first amount of the medical fluid from the reservoir; refill the reservoir with a second amount of the medical fluid; based on the air check protocol, perform an air check pressurization sequence by gathering air check compressibility data for the at least one syringe of the injector system; and based on the air check protocol, compare the air check compressibility data with the baseline compressibility data to determine a volume of air present in the reservoir.

Abstract: Described herein are novel systems for targeting, editing or manipulating DNA in a cell or cell free environment, using novel type V B-GEn.7 (SEQ ID NO: 1) and variants thereof, as well as methods and kits for manipulating DNA.

Abstract: The present application provides materials and methods for treating a patient with autosomal dominant RP, both ex vivo and in vivo; materials and methods for editing a RHO gene in a human cell; and materials and methods for editing a P23H mutation in a RHO gene in a human cell. In addition, the present application provides one or more gRNAs or sgRNAs for editing a RHO gene; one or more gRNAs or sgRNAs for editing a P23H mutation in a RHO gene; and a therapeutic comprising at least one or more gRNAs or sgRNAs for editing a P23H mutation in a RHO gene. The present application provides a therapeutic for treating a patient with autosomal dominant RP. The present application provides a kit for treating a patient with autosomal dominant RP. In addition, the present application provides a self-inactivating CRISPR-Cas system.

Abstract: A fluid injector system includes at least one injector for pressurizing and delivering at least one fluid from at least one fluid reservoir, at least one fluid path section providing fluid communication between a bulk fluid reservoir and a syringe connected to the at least one injector, and at least one sensor arranged along the at least one fluid path section. The at least one sensor includes an emitter configured to emit light through the at least one fluid path section, and a detector configured to receive the light emitted through the at least one fluid path section and generate an electrical signal based on at least one property of the received light.

Abstract: The present invention relates to carboxylic acid aromatic amides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a diseases a sole agent or in combination with other active ingredients.